unilife's products shows a weak business case , page-30

" facts are we completed the IA for Unifill in mid 2011. 30 months later how many Unifill are on the shelf with customers drugs in them?"

Indi, I think one may have to have a look at what was happening at that time with generic lovenox coming out during the IA. Sanofi were fighting against it happening but it happened and plans can change and focus can shift when large pharma are faced with a blockbuster facing generic competition. At least the focus is back on with Sanofi and we have a commitment from, not just for lovenox either, they have left that door open so they can take up the 150m minimum per annum.

Hopefully some pharma see that they need to act faster before their patent runs out and a generic enters the market, this way they can have enough lead time to house their drug in a superior safety syringe the consumer is used to and likes using, same with medical professionals.